Bharat Biotech's homegrown COVID-19 vaccine has shown an interim vaccine efficacy of 81% in late-stage clinical trials, the Indian company said on Wednesday.
The interim analysis was based on 43 recorded cases of COVID-19 in the trial of 25,800 participants, conducted in partnership with the Indian government's medical research body.
Thirty-six of the 43 cases were recorded in participants who received a placebo, compared with seven cases in people who were given the Bharat Biotech vaccine, pointing to an efficacy rate of 80.6%, the company said.
India had approved the vaccine, branded COVAXIN, in January without late-stage efficacy data, raising questions about its effectiveness.
India's vaccination drive, currently underway, includes COVAXIN and a vaccine developed by Oxford University and AstraZeneca.
Earlier this week, Indian Prime Minister Narendra Modi was inoculated with the first dose of COVAXIN.
At least 73 injured after Houthi rebels attack Saudi civilian and energy facilities
Nepal rescue focused on workers trapped in three tunnels
Indonesia reopens Jakarta airport, four others after Anak Krakatau ash clears
Russia hits Kyiv after brief pause for US envoys' visit, killing two
Kenya offers temporary amnesty to undocumented East Africans amid crackdown fears
7 Indonesian airports remain shut due to volcanic ash from Anak Krakatau
Bolivia confirms 9 deaths after military base explosion
Israeli strikes on southern Lebanese town kill 11, state news agency saysÂ
